The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•26 February 2026•

1 min read

Eli Lilly's Orforglipron Outperforms Oral Semaglutide in Phase 3 Trial

Key Facts

1Orforglipron 36 mg lowered A1C by 2.2% compared to 1.4% with oral semaglutide 14 mg.

2Participants on orforglipron lost 9.2% of body weight compared to 5.3% for the oral semaglutide group.

Eli Lilly (LLY) announced positive Phase 3 results for its oral GLP-1 candidate, orforglipron, demonstrating superior efficacy over Novo Nordisk's oral semaglutide. In the ACHIEVE-3 trial, orforglipron reduced A1C levels by 2.2%, significantly higher than the 1.4% reduction seen with the competitor's treatment. Participants using Lilly's candidate also achieved a 9.2% weight reduction, nearly doubling the 5.3% loss recorded in the semaglutide group. Unlike existing oral treatments, orforglipron is a small molecule that can be taken without specific food or water restrictions, offering a more convenient dosing profile. Eli Lilly anticipates potential U.S. regulatory approval for the drug by the second quarter of 2026, positioning the company to capture a larger share of the multi-billion dollar GLP-1 market.